A+ = 95.0+
A = 91.0-94.9
A- = 88.0-90.9
B+ = 85.0-87.9
B = 81.0-84.9
B- = 78.0-80.9
A = 91.0-94.9
A- = 88.0-90.9
B+ = 85.0-87.9
B = 81.0-84.9
B- = 78.0-80.9
C+ = 75.0-77.9
C = 71.0-74.9
C- = 68.0-70.9
D+ = 65.0-67.9
D = 61.0-64.9
D- = 58.0-60.9
F = <58.0
C = 71.0-74.9
C- = 68.0-70.9
D+ = 65.0-67.9
D = 61.0-64.9
D- = 58.0-60.9
F = <58.0
Based on KLAS' Decision Insights data, the market energy indicator reflects the frequency with which a vendor is seriously considered and replaced compared to what would be expected based on the number of vendors in the market and the number of purchase decisions recorded.
Market average: 80.1
Software average: 80.3
Overall performance score (100-point scale) |
Trend (2022-2023) |
Total evaluations |
Culture
|
Loyalty
|
Operations
|
Product
|
Relationship
|
Value
|
||
|
Bluesight
Protenus Diversion Analytics 
|
87.7 |
N/A
|
n=18
|
A-
|
A-
|
B
|
B+
|
A
|
A-
|
|
| |
|
|
|
|
||||||
|
Bluesight
ControlCheck (formerly Bluesight for Controlled Substances)
|
86.6 |
-5%
|
n=33
|
B
|
A-
|
B
|
B
|
A-
|
B+
|
|
| |
|
|
|
|
||||||
|
BD
HealthSight Diversion Management
|
79.5 |
N/A
|
n=24
|
C+
|
B
|
C+
|
C+
|
B
|
B-
|
|
50.0 |
100.0 |
|||||||||
87.7
n=18
culture
A-
loyalty
A-
operations
B
product
B+
relationship
A
value
A-
culture
B
loyalty
A-
operations
B
product
B
relationship
A-
value
B+
79.5
n=24
culture
C+
loyalty
B
operations
C+
product
C+
relationship
B
value
B-
Solutions Not Ranked
Ordered alphabetically
L
|
Overall Performance Score (100-point scale) |
Total evaluations |
Culture
|
Loyalty
|
Operations
|
Product
|
Relationship
|
Value
|
|
|
Bluesight
Medacist RxAuditor Investigate/RxAuditor L |
63.2 |
n=11
|
D-
|
F
|
C-
|
D
|
B
|
C+
|
| |
|
|
|
|
||||
|
Imprivata
FairWarning Drug Diversion Intelligence L |
64.6 |
n=15
|
F
|
D
|
C-
|
D
|
C
|
C-
|
| |
|
|
|
|
||||
|
Wolters Kluwer
Invistics Flowlytics L |
80.2 |
n=10
|
C
|
B
|
C+
|
B-
|
B
|
B
|
L
&nbps;
Bluesight
Medacist RxAuditor Investigate/RxAuditor L
Medacist RxAuditor Investigate/RxAuditor L
63.2
n=11
n=11
culture
D-
loyalty
F
operations
C-
product
D
relationship
B
value
C+
Imprivata
FairWarning Drug Diversion Intelligence L
FairWarning Drug Diversion Intelligence L
64.6
n=15
n=15
culture
F
loyalty
D
operations
C-
product
D
relationship
C
value
C-
Wolters Kluwer
Invistics Flowlytics L
Invistics Flowlytics L
80.2
n=10
n=10
culture
C
loyalty
B
operations
C+
product
B-
relationship
B
value
B
Other Notable Performances
Other Notable Performances
Ranked solutions for which at least 95% of respondents answered yes.
Avoids charging for every little thing?
Protenus
Diversion Analytics
Diversion Analytics
n=15 100%
Part of long-term plans?
BD
HealthSight Diversion Management
HealthSight Diversion Management
n=21 96%
Avoids charging for every little thing?
Protenus
Diversion Analytics
Diversion Analytics
n=15 100%
Part of Long Term Plans?
BD
HealthSight Diversion Management
HealthSight Diversion Management
n=21 96%
